Skip to main content
Back
NAMS logo

NewAmsterdam Pharma Company N.V.

Data quality: 100%
NAMS
NASDAQ Healthcare Biotechnology
$30.01
▲ $1.07 (3.70%)
Mkt Cap: 3.45B
Day Range
$28.81 $30.53
52-Week Range
$14.06 $42.00
Volume
777,580
50D / 200D Avg
$32.70 / $29.92
Prev Close
$28.94

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E -16.9 0.4
P/B 5.1 2.9
ROE % -28.3 3.7
Net Margin % -905.7 3.9
Rev Growth 5Y % 10.0
D/E 0.0 0.2

Analyst Price Target

Hold
$47.20 +57.3%
Low: $37.00 High: $55.00
Forward EPS
-$1.91
Est. Revenue
28 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $3.66
-$0.01 – $13.82
1.3 B 6
FY2029 $1.59
$0.00 – $6.00
830 M 6
FY2028 -$0.21
-$0.81 – $0.00
430 M 7

Key Takeaways

Debt/Equity of 0.00 — conservative balance sheet
Negative free cash flow of -148.03M
PEG of 0.62 suggests growth is underpriced
Capital efficient — spends only 1.09% of revenue on capex

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)-50.61%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-28.29%
ROIC-24.76%
Net Margin-905.74%
Op. Margin-1002.90%

Safety

Debt / Equity
0.00
Current Ratio7.88
Interest Coverage0.00

Valuation

P/E Ratio
-16.93
P/B Ratio5.05
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -50.61% Revenue Growth (3Y) 26.38%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 22.50M Net Income (TTM) -203.82M
ROE -28.29% ROA -26.49%
Gross Margin 99.74% Operating Margin -1002.90%
Net Margin -905.74% Free Cash Flow (TTM) -148.03M
ROIC -24.76% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.00 Current Ratio 7.88
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -16.93 P/B Ratio 5.05
P/S Ratio 153.33 PEG Ratio 0.62
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 3.45B Enterprise Value 2.96B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 22.50M 45.56M 14.09M 102.69M 0.0
Net Income -203.82M -241.60M -176.94M -22.63M -41.79M
EPS (Diluted) -1.75 -2.56 -2.15 -1.19 -3.34
Gross Profit 22.44M 45.56M 14.09M 102.69M 0.0
Operating Income -225.68M -176.29M -182.97M -3.56M -34.98M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 769.28M 864.62M 347.10M 478.50M 67.99M
Total Liabilities 85.85M 107.12M 58.70M 48.43M 11.36M
Shareholders' Equity 683.43M 757.50M 288.39M 430.07M 56.63M
Total Debt 202,000.0 448,000.0 60,000.0 126,000.0 186,511.0
Cash & Equivalents 490.00M 771.74M 340.45M 467.73M 60.38M
Current Assets 675.70M 863.41M 346.79M 477.98M 66.96M
Current Liabilities 85.79M 106.92M 49.90M 36.06M 11.24M